サンプル依頼リスト カート
  • English
  • Korean
表紙：心臓バイオマーカーの世界市場：規模・予測 - タイプ別、用途別、最終用途別、地域別分析（2023年～2030年）
市場調査レポート
商品コード
1407962

心臓バイオマーカーの世界市場：規模・予測 - タイプ別、用途別、最終用途別、地域別分析（2023年～2030年）

Global Cardiac Biomarkers Market Size Study & Forecast, by Type, by Application, by End use, and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
心臓バイオマーカーの世界市場：規模・予測 - タイプ別、用途別、最終用途別、地域別分析（2023年～2030年）
出版日: 2023年12月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の心臓バイオマーカーの市場規模は、2022年に約160億5,000万米ドルに達し、予測期間2023年～2030年に14.6％超の健全な成長率で成長すると予測されています。 心臓バイオマーカーは、心臓の損傷やストレスに反応して血流に放出される分子です。

これらのバイオマーカーの評価は、心臓への血液供給不足を特徴とする急性冠症候群（ACS）や心臓虚血などの状態を診断するための貴重なツールです。さらに、心臓バイオマーカーの検査は、これらの病態を発症する個人のリスクを評価するのに役立ち、ACSや心臓虚血が疑われる個人のモニタリングや管理に役立っています。迅速な診断検査に対する需要の増加、心臓の健康を促進するイニシアチブの高まり、CVDの定期的なスクリーニング、高齢者人口の増加が、世界中で心臓バイオマーカーの需要を促進している主な要因です。

心臓発作や心不全を含むCVDの世界の有病率は増加しており、診断やモニタリングに役立つ心臓バイオマーカー検査の需要を牽引しています。世界保健機関（WHO）によると、心血管疾患（CVDs）は世界の主要な死因として記録されており、年間推定1,790万人の命が奪われています。さらに、心臓発作と脳卒中がこれらの心血管疾患による死亡の85％を占めています。さらに、2020年7月にCureus Journal of Medical Scienceに掲載された論文によると、虚血性心疾患（IHD）は世界的に重要な死因となっています。世界で約1億2,600万人（10万人当たり1,655人）、世界人口のおよそ1.72％が虚血性心疾患を患っています。2030年には人口10万人あたり1,845人以上が虚血性心疾患に罹患すると予測されています。その結果、CVDの発生件数の増加が、推定期間中の心臓バイオマーカー市場の成長を促進しています。さらに、ポイントオブケア（POC）心臓診断薬に対する需要の急増や迅速診断検査に対する需要の高まりは、予測期間中に様々な有利な機会をもたらします。しかし、心臓バイオマーカー検査に関連する複雑さと厳しい規制の枠組みが、2020年～2030年の予測期間を通じて市場成長の課題となっています。

心臓バイオマーカーの世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、確立された医療システムの存在と、様々な病状の診断・予測ツールとして心臓バイオマーカーが広く採用されていることから、2022年の市場を独占しました。高齢者人口の増加は、急性心筋梗塞などの病態を発見するためにバイオマーカー検査を必要とすることが多く、こうした検査製品の需要を支える原動力となっています。さらに、同地域にはQuidel CorporationやDanaher Corporationといった業界の主要企業が進出していることも、市場成長のさらなる要因となっています。一方、アジア太平洋は予測期間中に最も高いCAGRで成長すると予想されています。先進的な心臓検査へのアクセスの増加、進行中の近代化への取り組み、可処分所得の増加が重要な促進要因です。さらに、この地域では心血管疾患（CVD）の有病率が上昇しており、診断ツールの強化に対するニーズが高まっています。また、対象疾患研究のための政府資金援助や医療支出の増加も重要な役割を果たしています。他の発展途上国と比較して、インドはCVDの罹患率が高いです。心臓バイオマーカー診断薬はCVDの診断、評価、治療を可能にする極めて重要な役割を果たすため、このような大きな疾病負担が心臓バイオマーカー診断薬の需要を促進すると予想されます。

本調査の目的は、近年のさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面を取り入れるよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 心臓バイオマーカーの世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 業界の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 心臓バイオマーカーの世界市場力学

  • 心臓バイオマーカー市場の影響分析（2020年～2030年）
    • 市場促進要因
      • 迅速診断検査に対する需要の増加
      • 心血管疾患（CVD）の増加
    • 市場の課題
      • 心臓バイオマーカー検査に伴う複雑さ
      • 厳しい規制の枠組み
    • 市場機会
      • ポイントオブケア（POC）心臓診断薬に対する需要の急増
      • 迅速診断検査に対する需要の高まり

第4章 世界の心臓バイオマーカー市場産業分析

  • ポーターのファイブフォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターのファイブフォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 心臓バイオマーカーの世界市場：タイプ別

  • 市場スナップショット
  • 心臓バイオマーカーの世界市場：タイプ別、実績 - ポテンシャル分析
  • 心臓バイオマーカーの世界市場：タイプ別、推定・予測（2020年～2030年）
  • 心臓バイオマーカー市場：サブセグメント分析
    • トロポニン
    • CK-MB
    • ミオグロビン
    • BNPおよびNT-proBNP
    • その他

第6章 心臓バイオマーカーの世界市場：用途別

  • 市場スナップショット
  • 心臓バイオマーカーの世界市場：用途別、実績 - ポテンシャル分析
  • 心臓バイオマーカーの世界市場：用途別、推定・予測（2020年～2030年）
  • 心臓バイオマーカー市場：サブセグメント分析
    • 急性冠症候群
    • 心筋梗塞
    • うっ血性心不全
    • その他

第7章 心臓バイオマーカーの世界市場：最終用途別

  • 市場スナップショット
  • 心臓バイオマーカーの世界市場：最終用途別、実績 - ポテンシャル分析
  • 心臓バイオマーカーの世界市場：最終用途別、推定・予測（2020年～2030年）
  • 心臓バイオマーカー市場：サブセグメント分析
    • ラボ検査
    • ポイントオブケア（POC）検査

第8章 心臓バイオマーカーの世界市場：地域分析

  • 主要国
  • 主要新興国
  • 心臓バイオマーカー市場：地域市場スナップショット
  • 北米
    • 米国
      • タイプの推定・予測（2020年～2030年）
      • 用途の推定・予測（2020年～2030年）
      • 最終用途の推定・予測（2020年～2030年）
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東・アフリカ

第9章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Abbott
    • Quidel Corporation
    • Siemens Healthcare GmbH
    • F. Hoffmann-La Roche Ltd.
    • Danaher Corporation
    • BIOMERIEUX
    • Bio-Rad Laboratories, Inc.
    • Randox Laboratories Ltd.
    • Creative Diagnostics
    • Life Diagnostics, Inc.

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Cardiac Biomarkers Market, report scope
  • TABLE 2. Global Cardiac Biomarkers Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Cardiac Biomarkers Market estimates & forecasts by Type 2020-2030 (USD Billion)
  • TABLE 4. Global Cardiac Biomarkers Market estimates & forecasts by Application 2020-2030 (USD Billion)
  • TABLE 5. Global Cardiac Biomarkers Market estimates & forecasts by End use 2020-2030 (USD Billion)
  • TABLE 6. Global Cardiac Biomarkers Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Cardiac Biomarkers Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Cardiac Biomarkers Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Cardiac Biomarkers Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Cardiac Biomarkers Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Cardiac Biomarkers Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Cardiac Biomarkers Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Cardiac Biomarkers Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Cardiac Biomarkers Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Cardiac Biomarkers Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. U.S. Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. Canada Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. Canada Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. UK Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. UK Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. Germany Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. Germany Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. France Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. France Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. Italy Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Italy Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Spain Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Spain Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. RoE Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. RoE Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. China Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. China Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. India Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. India Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. Japan Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. Japan Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. South Korea Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. South Korea Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. Australia Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. Australia Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. Brazil Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Brazil Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Mexico Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Mexico Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. RoLA Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. RoLA Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. Saudi Arabia Cardiac Biomarkers Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. South Africa Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoMEA Cardiac Biomarkers Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Cardiac Biomarkers Market
  • TABLE 71. List of primary sources, used in the study of global Cardiac Biomarkers Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Cardiac Biomarkers Market, research methodology
  • FIG 2. Global Cardiac Biomarkers Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Cardiac Biomarkers Market, key trends 2022
  • FIG 5. Global Cardiac Biomarkers Market, growth prospects 2023-2030
  • FIG 6. Global Cardiac Biomarkers Market, porters 5 force model
  • FIG 7. Global Cardiac Biomarkers Market, pest analysis
  • FIG 8. Global Cardiac Biomarkers Market, value chain analysis
  • FIG 9. Global Cardiac Biomarkers Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Cardiac Biomarkers Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Cardiac Biomarkers Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Cardiac Biomarkers Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Cardiac Biomarkers Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Cardiac Biomarkers Market, regional snapshot 2020 & 2030
  • FIG 15. North America Cardiac Biomarkers Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Cardiac Biomarkers Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Cardiac Biomarkers Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Cardiac Biomarkers Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Cardiac Biomarkers Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Cardiac Biomarkers Market is valued at approximately USD 16.05 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 14.6% over the forecast period 2023-2030. Cardiac biomarkers are molecules released into the bloodstream in response to heart damage or stress. The assessment of these biomarkers is a valuable tool in the diagnosis of conditions such as Acute Coronary Syndrome (ACS) and cardiac ischemia, both of which are characterized by inadequate blood supply to the heart. Additionally, tests for cardiac biomarkers serve to evaluate an individual's risk of developing these conditions and are instrumental in monitoring and managing individuals with suspected ACS and cardiac ischemia. The increasing demand for rapid diagnostic tests, the rise in initiatives to promote heart health, and regular screening for CVDs, along with the increasing aging population are the key factors that are fueling the demand for cardiac biomarkers across the globe.

The global prevalence of CVDs, including heart attacks and heart failure, is increasing, driving the demand for cardiac biomarker tests to aid in diagnosis and monitoring. According to the World Health Organization (WHO), it was estimated that Cardiovascular Diseases (CVDs) are recorded as the leading cause of death around the world, which takes an estimated 17.9 million lives annually. Additionally, heart attacks and strokes account for 85% of these cardiovascular disease deaths. In addition, according to an article that was published in the Cureus Journal of Medical Science in July 2020, Ischemic Heart Disease (IHD) is a significant cause of death globally. Around 126 million people worldwide (1,655 per 100,000), or roughly 1.72% of the world's population, suffer from ischemic heart disease. It is anticipated that more than 1,845 cases of ischemic heart disease per 100,000 people worldwide by 2030. Consequentially, the rise in incidences of CVDs are propelling the growth of the Cardiac Biomarkers Market during the estimated period. Moreover, the surge in demand for Point-of-Care (POC) cardiac diagnostics, as well as the growing demand for rapid diagnostic tests present various lucrative opportunities over the forecast years. However, the complexities associated with cardiac biomarker tests and the stringent regulatory frameworks are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Cardiac Biomarkers Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of a well-established healthcare system and the widespread adoption of cardiac biomarkers as a diagnostic and predictive tool for various medical conditions. The increasing elderly population, often in need of biomarker testing to detect conditions such as acute myocardial infarction, is a driving force behind the demand for these testing products. Furthermore, the presence of key industry players such as Quidel Corporation and Danaher Corporation in the region is an additional contributing factor to the market's growth. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increasing accessibility to advanced cardiac tests, ongoing modernization efforts, and rising disposable incomes are significant contributing factors. Moreover, the escalating prevalence of cardiovascular diseases (CVDs) in this region has led to a heightened need for enhanced diagnostic tools. Government funding for targeted disease research and increased healthcare spending are also playing crucial roles. In comparison to other developing nations, India stands out with a higher incidence of CVDs. This substantial disease burden is anticipated to fuel the demand for cardiac biomarker diagnostics, as they play a pivotal role in enabling the diagnosis, assessment, and treatment of CVDs.

Major market players included in this report are:

  • Abbott
  • Quidel Corporation
  • Siemens Healthcare GmbH
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • BIOMERIEUX
  • Bio-Rad Laboratories, Inc.
  • Randox Laboratories Ltd.
  • Creative Diagnostics
  • Life Diagnostics, Inc.

Recent Developments in the Market:

  • In November 2022, OMRON Healthcare and CardioSignal announced the company's partnership agreement to develop early cardiovascular disease detection technology for cardiac health management. This partnership presents digital cardiac biomarkers that potentially save lives.
  • In April 2021, Roche announced a series of five new planned uses for two important cardiac biomarkers (cTnT-hs) using the Elecsys technology, which has the very sensitive cardiac troponin T and NT-proBNP. This helps in improving risk detection and diagnosis and enables the company to make additional revenues from its current product line.

Global Cardiac Biomarkers Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Type, Application, End use, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

  • Troponin
  • CK-MB
  • Myoglobin
  • BNP and NT-proBNP
  • Others

By Application:

  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Congestive Heart Failure
  • Others

By End use:

  • Laboratory Testing
  • Point of Care Testing

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Cardiac Biomarkers Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Cardiac Biomarkers Market, by Type, 2020-2030 (USD Billion)
    • 1.2.3. Cardiac Biomarkers Market, by Application, 2020-2030 (USD Billion)
    • 1.2.4. Cardiac Biomarkers Market, by End use, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Cardiac Biomarkers Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Cardiac Biomarkers Market Dynamics

  • 3.1. Cardiac Biomarkers Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing demand for rapid diagnostic tests
      • 3.1.1.2. Rise in incidences of cardiovascular diseases (CVDs)
    • 3.1.2. Market Challenges
      • 3.1.2.1. Complexities associated with cardiac biomarkers tests
      • 3.1.2.2. Stringent regulatory frameworks
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Surge in demand for Point-of-Care (POC) cardiac diagnostics
      • 3.1.3.2. Growing demand for rapid diagnostic tests

Chapter 4. Global Cardiac Biomarkers Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Cardiac Biomarkers Market, by Type

  • 5.1. Market Snapshot
  • 5.2. Global Cardiac Biomarkers Market by Type, Performance - Potential Analysis
  • 5.3. Global Cardiac Biomarkers Market Estimates & Forecasts by Type 2020-2030 (USD Billion)
  • 5.4. Cardiac Biomarkers Market, Sub Segment Analysis
    • 5.4.1. Troponin
    • 5.4.2. CK-MB
    • 5.4.3. Myoglobin
    • 5.4.4. BNP and NT-proBNP
    • 5.4.5. Others

Chapter 6. Global Cardiac Biomarkers Market, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Cardiac Biomarkers Market by Application, Performance - Potential Analysis
  • 6.3. Global Cardiac Biomarkers Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
  • 6.4. Cardiac Biomarkers Market, Sub Segment Analysis
    • 6.4.1. Acute Coronary Syndrome
    • 6.4.2. Myocardial Infarction
    • 6.4.3. Congestive Heart Failure
    • 6.4.4. Others

Chapter 7. Global Cardiac Biomarkers Market, by End use

  • 7.1. Market Snapshot
  • 7.2. Global Cardiac Biomarkers Market by End use, Performance - Potential Analysis
  • 7.3. Global Cardiac Biomarkers Market Estimates & Forecasts by End use 2020-2030 (USD Billion)
  • 7.4. Cardiac Biomarkers Market, Sub Segment Analysis
    • 7.4.1. Laboratory Testing
    • 7.4.2. Point of Care Testing

Chapter 8. Global Cardiac Biomarkers Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Cardiac Biomarkers Market, Regional Market Snapshot
  • 8.4. North America Cardiac Biomarkers Market
    • 8.4.1. U.S. Cardiac Biomarkers Market
      • 8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. End use breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Cardiac Biomarkers Market
  • 8.5. Europe Cardiac Biomarkers Market Snapshot
    • 8.5.1. U.K. Cardiac Biomarkers Market
    • 8.5.2. Germany Cardiac Biomarkers Market
    • 8.5.3. France Cardiac Biomarkers Market
    • 8.5.4. Spain Cardiac Biomarkers Market
    • 8.5.5. Italy Cardiac Biomarkers Market
    • 8.5.6. Rest of Europe Cardiac Biomarkers Market
  • 8.6. Asia-Pacific Cardiac Biomarkers Market Snapshot
    • 8.6.1. China Cardiac Biomarkers Market
    • 8.6.2. India Cardiac Biomarkers Market
    • 8.6.3. Japan Cardiac Biomarkers Market
    • 8.6.4. Australia Cardiac Biomarkers Market
    • 8.6.5. South Korea Cardiac Biomarkers Market
    • 8.6.6. Rest of Asia Pacific Cardiac Biomarkers Market
  • 8.7. Latin America Cardiac Biomarkers Market Snapshot
    • 8.7.1. Brazil Cardiac Biomarkers Market
    • 8.7.2. Mexico Cardiac Biomarkers Market
  • 8.8. Middle East & Africa Cardiac Biomarkers Market
    • 8.8.1. Saudi Arabia Cardiac Biomarkers Market
    • 8.8.2. South Africa Cardiac Biomarkers Market
    • 8.8.3. Rest of Middle East & Africa Cardiac Biomarkers Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Abbott
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Quidel Corporation
    • 9.3.3. Siemens Healthcare GmbH
    • 9.3.4. F. Hoffmann-La Roche Ltd.
    • 9.3.5. Danaher Corporation
    • 9.3.6. BIOMERIEUX
    • 9.3.7. Bio-Rad Laboratories, Inc.
    • 9.3.8. Randox Laboratories Ltd.
    • 9.3.9. Creative Diagnostics
    • 9.3.10. Life Diagnostics, Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption